Comparative Pharmacology
Head-to-head clinical analysis: ANGELIQ versus DEPO TESTADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGELIQ versus DEPO TESTADIOL.
ANGELIQ vs DEPO-TESTADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angeliq combines drospirenone, a spironolactone analogue with antimineralocorticoid and antiandrogenic activity, and estradiol, an estrogen that replaces endogenous estrogen and regulates gonadotropin secretion.
Testosterone cypionate binds to androgen receptors, modulating gene transcription and promoting male secondary sexual characteristics. Estradiol cypionate binds to estrogen receptors, regulating female reproductive function and bone metabolism.
One tablet (drospirenone 0.5 mg/estradiol 1 mg) orally once daily.
1 mL (50 mg testosterone enanthate / 2 mg estradiol valerate) intramuscularly every 4 weeks.
None Documented
None Documented
Estradiol: terminal half-life 13-18 hours; Drospirenone: terminal half-life 25-32 hours, allowing once-daily dosing.
Testosterone cypionate: approximately 8 days after intramuscular injection due to slow release from oil depot; estradiol cypionate: approximately 5-7 days. Clinically, steady-state concentrations require 4-6 weeks of every-4-week dosing.
Estradiol: renal (90%) as conjugates (glucuronide and sulfate), fecal (10%). Drospirenone: renal (50%) as inactive metabolites, fecal (50%) as metabolites; less than 1% excreted unchanged.
Renal: 90% (metabolites, primarily glucuronide and sulfate conjugates of testosterone and estradiol); Fecal: <10% (biliary excretion of conjugates, minimal enterohepatic recirculation); Unchanged drug: negligible.
Category C
Category C
Hormone Replacement Therapy
Hormone Replacement Therapy